Clinical Trials on Acral Lentiginous Melanoma

Total 3266 results

University of Turku

Completed

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Metastatic Melanoma

Finland
University Hospital Tuebingen

Completed

Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

Malignant Melanoma

Germany
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Stage IV Uveal Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Withdrawn

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
Medical University of Graz
Bristol-Myers Squibb

Terminated

The IRMI-FMT Trial

Malignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota Transplantation

Austria
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Malignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Completed

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
Replimune Inc.

Not yet recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

Advanced Melanoma
Hull University Teaching Hospitals NHS Trust

Not yet recruiting

EVALUATING THE CURRENT STANDARD OF CARE FOR PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA OF THE HEAD AND NECK - ACCESS TO STAGING AND SURGICAL TREATMENT

Melanoma | Melanoma (Skin)
University Hospital, Basel, Switzerland
Anaveon AG

Recruiting

ACT-TIL and ANV419 for Advanced Melanoma. (BaseTIL-03M)

Advanced Melanoma

Switzerland
Centre Hospitalier Universitaire de Nice

Recruiting

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors (mela-quantif)

Melanoma (Skin)

France
Institut Jean-Godinot
Université de Reims Champagne-Ardenne

Not yet recruiting

Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma (Helioma)

Metastatic Melanoma
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
Henan Cancer Hospital

Recruiting

PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

Advanced Melanoma

China
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma

Mucosal Melanoma

China
Memorial Sloan Kettering Cancer Center
Pfizer

Recruiting

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Peking University Cancer Hospital & Institute

Recruiting

Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut

Advanced Melanoma

China
First Affiliated Hospital of Zhejiang University

Recruiting

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

Malignant Melanoma

China
John Kirkwood
Bristol-Myers Squibb; Secura Bio, Inc.

Recruiting

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Unresectable Melanoma

United States
Fudan University

Recruiting

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Malignant Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

Mucosal Melanoma

China
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Recruiting

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)

Recruiting

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (RadVax)

Metastatic Melanoma

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute

Recruiting

GI Complications in Cancer Immunotherapy Patients

Malignant Melanoma

United States
ImmVira Pharma Co. Ltd

Suspended

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Melanoma | Malignant Melanoma

United States
Institut Curie

Completed

Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU) (ctDNA MU)

Choroidal Melanoma

France
University of Chicago
Merck Sharp & Dohme LLC; Evelo Biosciences, Inc.

Suspended

Pembrolizumab and EDP1503 in Advanced Melanoma

Melanoma | Melanoma (Skin)

United States
Agenus Inc.

Suspended

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Advanced Melanoma

United States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
Anthony Joshua, FRACP
St Vincent's Hospital, Sydney

Active, not recruiting

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM)

Ocular Melanoma

Australia
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
RAPT Therapeutics, Inc.

Terminated

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Advanced Melanoma

United States
European Organisation for Research and Treatment...

Active, not recruiting

Minimal SN Tumor Burden (Minitub)

Cutaneous Melanoma

France, Italy, Switzerland, Belgium, Netherlands, Germany, Poland, Slovenia, United Kingdom, Spain
Lytix Biopharma AS
Laboratory Corporation of America; OWL

Active, not recruiting

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (ATLAS-IT-05)

Advanced Melanoma

United States, Spain, France, Norway
Biocad

Active, not recruiting

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Melanoma (Skin)

Russian Federation
Centre Hospitalier Universitaire de Nice

Completed

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes (EXOSOMES)

Metastatic Melanoma

France
Abramson Cancer Center at Penn Medicine
ImaginAb, Inc.

Enrolling by invitation

Zr89 + PET Companion Trial

Melanoma (Skin)

United States
University Hospital, Essen

Active, not recruiting

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem)

Malignant Melanoma

Germany, France, Greece, Serbia
Suthee Rapisuwon
Bristol-Myers Squibb

Active, not recruiting

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Melanoma | Ocular Melanoma

United States

Clinical Trials on Acral Lentiginous Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations